Form 4: Teva Executive Sells Over 62,000 Shares

Mark Sabag, Teva Pharmaceutical's EVP of International Markets Commercial, sold 62,102 ordinary shares for approximately $30.14 per share.

Summary

• Mark Sabag, Executive Vice President, International Markets Commercial of Teva Pharmaceutical Industries Ltd., reported a sale of company shares.
• On March 17, 2026, Sabag disposed of 62,102 Ordinary Shares.
• The shares were sold at a weighted average price of $30.141 per share, with prices ranging from $30.115 to $30.215.
• Following this transaction, Sabag beneficially owns 224,940 Ordinary Shares directly.
• The Ordinary Shares may be represented by American Depositary Shares (ADS), where each ADS currently represents one Ordinary Share.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative signal due to an executive selling a notable number of shares, though it could be for personal financial reasons rather than a reflection of company performance.

Negatives

• An insider, Mark Sabag, sold a notable number of shares (62,102), which could be interpreted by some investors as a potential lack of confidence in the company's near-term prospects, although it could also be for personal financial planning.

Future Outlook

NA

Management Comments

• The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.115 to $30.215, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that insider sales, especially by high-ranking executives, are closely watched by the market as they can sometimes signal management's perception of future company performance. However, such sales are also common for personal financial planning, diversification, or tax purposes, and without additional context, it is difficult to definitively interpret the implications for Teva Pharmaceutical Industries Ltd.

Stakeholder Impact

• Shareholders: May view the insider sale as a potential negative signal, though the impact is likely minor unless a pattern of significant insider selling emerges.

Key Dates

Recommendation

A single insider sale by an executive, while noteworthy, does not fundamentally alter the investment thesis for Teva Pharmaceutical Industries Ltd. It could be for personal financial planning or diversification. Investors should monitor future insider activity and focus on the company's core financial performance and strategic initiatives rather than reacting solely to this transaction.

Keywords

Teva Pharmaceutical Industries, TEVA, Mark Sabag, Insider Sale, Form 4, Executive Stock Sale, Ordinary Shares, American Depositary Shares